Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Allogeneic, BCMA, CD19 Jul 23 | 2020Thoughts on Fate Therapeutics Updates to their CAR-T Programs in DLBCL and MM; Q1 2020 CallPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, SGLT2i Jul 21 | 2020Lexicon Reports Remaining Topline Ph3 Sota T2DM Results; Biocon Partners with Voluntis For Digital Insulin SolutionPurchase Blast
$599
Posted in: Glucose Monitoring Jul 20 | 2020Thoughts on UHC's New T2DM-focused Digital Care Platform (Level2); Implications to Dexcom and Other Coaching SolutionsPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Insulin Delivery Jul 20 | 2020IQVIA/JDRF Partner for T1DM Research; MannKind Hires Former Medtronic Exec as CCO; Insulet Initiates Horizon Preschool Trial; Adocia Q2 '20 Earnings; Dario Partners for UK DistributionPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, SGLT2i Jul 20 | 2020High-dose Trulicity CHMP Opinion this week?; CHMP Agenda July 20-23Purchase Blast
$599
Posted in: BCMA, CAR-T Jul 20 | 2020JNJ BCMA CAR-T, JNJ-4528, US filing on track for YE 2020, but EU delayed to H1 2021; JNJ Q2 2020 earnings callPurchase Blast
$599
Posted in: Glucose Monitoring, SGLT2i Jul 16 | 2020New Farxiga hHF Post-MI Study (DAPA-MI) Receives Fast Track Designation; Abbott and J&J Q2 '20 Earnings Updates; Dexcom G6 Temporary Approval in Pregnancy by Health CanadaPurchase Blast
$599
Posted in: Autologous Jul 16 | 2020Thoughts on Autolus’s Preclinical Pipeline Update; AACR II 2020 Investor Call SummaryPurchase Blast
$599
Posted in: Basal Insulin Jul 15 | 2020Oramed Oral Insulin End-of-Ph2 FDA Meeting Provides Ph3 Development ClarityPurchase Blast
$599
Posted in: Allogeneic, BCMA, CD19 Jul 14 | 2020Thoughts on Precision’s Allogeneic CAR-T Programs in NHL and MM; Q1 2020 CallPurchase Blast
$599
Posted in: Basal Insulin Jul 10 | 2020Novo's First Ph3 Icodec Trial (ONWARDS 1) Posted on CT.govPurchase Blast
$599
Posted in: Other, SGLT2i Jul 09 | 2020Bayer Reports Finerenone T2DM DKD Renal Outcomes Trial Topline Results (FIDELIO-DKD) ; EMPEROR-Reduced at ESC 2020Purchase Blast
$599
Posted in: Insulin Delivery Jul 09 | 2020Tandem and Medtronic Enter Into "Non-exclusive Patent Cross-license Agreement"Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jul 09 | 2020First Libre 3 Clinical Study InitiatedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jul 08 | 2020Tandem Partners with JDRF for Diabetes Device Education Campaign; Livongo's myStrength App Available for Free to Priority Health MembersPurchase Blast
$599
Posted in: Glucose Monitoring Jul 07 | 2020Nemaura Files PMA for Non-invasive CGM; Medtronic launches Mio Advance Infusion SetPurchase Blast
$599
Posted in: Basal Insulin Jul 06 | 2020New Lilly QW Insulin Ph2 Trials in T1DM and T2DMPurchase Blast
$599
Posted in: Autologous, CAR-T, CD19 Jul 03 | 2020Novartis Ph1b PORTIA Results Presented at Virtual AACR IIPurchase Blast
$599
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Jul 03 | 2020Two New Gracell Early Ph1 Trials in MM and NHL PostedPurchase Blast
Get the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
